Akero Therapeutics Elects New Directors at Annual Meeting

Akero Therapeutics ( (AKRO) ) has provided an announcement.

On June 3, 2025, Akero Therapeutics held its Annual Meeting of Stockholders where key decisions were made. Stockholders elected Judy Chou, Ph.D., and Tomas Heyman as Class III directors for a three-year term, ratified Deloitte & Touche LLP as the independent auditor for 2025, and approved the executive compensation package through a non-binding advisory vote.

The most recent analyst rating on (AKRO) stock is a Buy with a $69.00 price target. To see the full list of analyst forecasts on Akero Therapeutics stock, see the AKRO Stock Forecast page.

Spark’s Take on AKRO Stock

According to Spark, TipRanks’ AI Analyst, AKRO is a Neutral.

Akero’s stock score reflects strong technical momentum and positive corporate developments, which are key drivers. However, financial challenges with no current revenue and operational losses weigh down the overall score. The promising clinical trial results provide a potential catalyst for future growth.

To see Spark’s full report on AKRO stock, click here.

More about Akero Therapeutics

Akero Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for serious metabolic diseases.

Average Trading Volume: 1,434,207

Technical Sentiment Signal: Buy

Current Market Cap: $4.04B

For a thorough assessment of AKRO stock, go to TipRanks’ Stock Analysis page.